SecurityRDUS / Radius Health, Inc. (750469207)
IndustryPharmaceutical Preparations
Common Shares Outstanding45,076,508 shares (as of 2017-12-31)
Total Insiders42
Total Directors12
Total Officers11

Stock Insider Trading (from SEC Form 4)

Radius Health, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RDUS / Radius Health, Inc. insiders include MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC, Scopa James Paul, Foley Todd, STEINMETZ MICHAEL, GADICKE ANSBERT, Dere Willard H, KAILIAN VAUGHN M, MPM BIOVENTURES III L.P., SIMON NICHOLAS J III, MPM BioVentures IV GP LLC, HENNER DENNIS, AUERBACH ALAN H, Snow David P., Kelly Joseph Francis, Muenchbach Martin, FRIEDMAN CATHY, WHEELER KURT, Williams Gregory C., MPM BIOVENTURES III PARALLEL FUND, L.P., Harvey Brian Nicholas, BIOTECH GROWTH N V, Hughes Owen, MPM Bio IV NVS Strategic Fund LP, BB BIOTECH AG, MPM BIOVENTURES III LLC, MPM BIOVENTURES III GP L.P., Carmona Jose, and Hoiland Jesper Rosenberg Anthony, Purandare Dinesh, Roychowdhury Debasish, Fitzpatrick Lorraine A., Ward Robert, Hattersley Gary, GALAKATOS NICHOLAS, Graves Kurt, EVNIN LUKE, GARNIER JEAN PIERRE, Hatzis-Schoch Brent, MPM BIOVENTURES III GMBH & CO. Beteiligungs KG, MPM BIOVENTURES III-QP L.P., MPM BioVentures IV LLC, .

Insider Roster

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-04-19 4 BIOTECH GROWTH N V P D 33.7984 40,000 6,050,913 204,511,178
2018-04-12 4 BIOTECH GROWTH N V X D 14.004 107,114 6,010,913
2018-04-05 4 BIOTECH GROWTH N V P D 36.5769 50,000 5,903,799 215,942,666
2018-03-02 4 BIOTECH GROWTH N V P D 32.5181 80,000 5,853,799 190,354,421
2018-02-09 4 BIOTECH GROWTH N V P D 34.3835 75,000 5,773,799 198,523,418
2017-11-14 4 BIOTECH GROWTH N V P D 26.2478 50,000 5,698,799 149,580,936
2017-11-10 4 Hatzis-Schoch Brent P D 28.0893 1,778 2,278 63,987
2017-11-07 4 Hoiland Jesper P D 29.0368 6,800 12,900 374,575
2017-11-03 4 BIOTECH GROWTH N V P D 29.1515 50,000 5,648,799 164,670,964
2017-10-26 4 BIOTECH GROWTH N V P D 30.951 50,000 5,598,799 173,288,428
2017-10-25 4 BIOTECH GROWTH N V P D 32.8483 50,000 5,548,799 182,268,614
2017-09-15 4 Hoiland Jesper P D 32.7227 6,100 6,100 199,608
2017-09-14 4 Carmona Jose P D 32.8343 3,000 3,000 98,503
2017-09-14 4 BIOTECH GROWTH N V P D 32.9445 50,000 5,498,799 181,155,184
2017-09-13 4 BIOTECH GROWTH N V P D 33.7075 100,000 5,448,799 183,665,392
2017-09-12 4 BIOTECH GROWTH N V P D 35.4164 50,000 5,348,799 189,435,205
2017-09-05 4 BIOTECH GROWTH N V P D 36.7525 50,000 5,298,799 194,744,110
2017-08-16 4 BIOTECH GROWTH N V P D 35.9756 60,000 5,248,799 188,828,693
2017-08-10 4 BIOTECH GROWTH N V P D 34.26 75,000 5,188,799 177,768,254
2017-08-09 4 BIOTECH GROWTH N V P D 35.6737 75,000 5,113,799 182,428,131
2017-05-30 4 BIOTECH GROWTH N V P D 34.2087 40,000 5,038,799 172,370,763
2017-05-25 4 BIOTECH GROWTH N V P D 36.2505 40,000 4,998,799 181,208,963
2017-05-18 4 BIOTECH GROWTH N V P D 34.4069 50,000 4,958,799 170,616,901
2017-05-17 4 BIOTECH GROWTH N V P D 32.9812 18,000 4,908,799 161,898,082
2017-05-16 4 BIOTECH GROWTH N V P D 33.925 17,000 4,890,799 165,920,356
2017-05-12 4 BIOTECH GROWTH N V P D 33.9997 15,000 4,873,799 165,707,704
2017-05-09 4 BIOTECH GROWTH N V P D 35.9296 50,000 4,858,799 174,574,705
2017-05-08 4 BIOTECH GROWTH N V P D 35.5978 22,800 4,808,799 171,182,665
2017-05-05 4 BIOTECH GROWTH N V P D 35.5477 20,600 4,785,999 170,131,257
2017-05-02 4 BIOTECH GROWTH N V P D 33.9056 75,000 4,765,399 161,573,712
2017-05-01 4 BIOTECH GROWTH N V P D 35.3907 150,000 4,690,399 165,996,504
2017-04-25 4 Harvey Brian Nicholas M D 2.74 39,616 76,189
2017-03-21 4 BIOTECH GROWTH N V P D 35.8325 50,000 4,540,399 162,693,847
2017-03-20 4 Harvey Brian Nicholas M D 2.05 23,416 36,573
2017-03-17 4 BIOTECH GROWTH N V P D 38.4083 30,000 4,490,399 172,468,592
2017-03-15 4 BIOTECH GROWTH N V P D 39.956 44,469 4,460,399 178,219,702
2017-03-14 4 BIOTECH GROWTH N V P D 39.9993 17,252 4,415,930 176,634,109
2017-03-10 4 BIOTECH GROWTH N V P D 39.1673 38,279 4,398,678 172,284,341
2016-10-25 4 Ward Robert M D 7.8 10,000 15,000
2016-09-27 4 MPM BIOVENTURES III LLC J I -1,229,902 2,459,804
2016-09-27 4 GALAKATOS NICHOLAS J I -1,229,902 2,459,804
2016-09-27 4 GADICKE ANSBERT J I -1,943,751 3,887,502
2016-09-27 4 EVNIN LUKE J I -1,943,751 3,887,502
2016-09-27 4 MPM BioVentures IV LLC J I -713,849 1,427,698
2016-01-25 4 Fitzpatrick Lorraine A. P D 37.97 100 200 7,594
2015-11-25 4 Fitzpatrick Lorraine A. P D 60.595 100 100 6,060
2016-01-22 4 BIOTECH GROWTH N V P D 31.6658 38,259 4,360,399 138,075,523
2016-01-13 4 BIOTECH GROWTH N V P D 39.8977 50,000 4,322,140 172,443,445
2015-11-23 4 Ward Robert S D 62.765 -25,000 0
2015-11-23 4 Ward Robert M D 7.80 25,000 25,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
RDUS: Radius Health Analysis and Research Report

2018-05-04 - Asif

Overview Radius Health is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, its first commercial product, TYMLOSTM (abaloparatide) injection, was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In May 2017, the company commenced U.S. commercial sales of TYMLOS and, as of February 2018, TYMLOS was available and covered for approximately 259 million U.S. insured lives, representing approximately 86% of U.S. insured lives. In May 2017, the company also announced positive top-line results from its completed 24-month ACTIVExtend clinical trial for TYMLOS, which met all of ...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

18h seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far. (688-3)

Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss

2018-05-11 zacks
Radius Health, Inc. (RDUS - Free Report) reported a loss of $1.37 per share in the first quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of $1.43 but wider than the year-ago period loss of $1.32. Increase in general and administrative expenses led to the wider than anticipated net loss year over year. (126-0)

Radius Health, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by Radius Health, Inc. in conjunction with their 2018 Q1 earnings call. (28-0)

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

2018-05-07 seekingalpha
The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire. (603-2)